BioLineRx and Hemispherian to present GLIX1 data at EANO 2026

Thu, 10 Sep 2026 07:00:35 -0400

BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS announced that two abstracts on their GLIX1 compound have been accepted for presentation at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026), scheduled for September 24-27 in Rome, Italy.

One abstract has been selected for a mini-oral presentation on September 25, featuring preclinical efficacy data for GLIX1 in orthotopic glioblastoma models. The presentation will be delivered by Hemispherian Chief Scientific Officer Dr. Adam Robertson and will cover results from two orthotopic cell-derived xenograft glioblastoma models and a temozolomide-resistant patient-derived xenograft model. Preclinical data showed dose-dependent tumor growth inhibition and survival benefit

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

Thu, 10 Sep 2026 07:00:00 -0400

TEL AVIV, Israel and OSLO, Norway, Sept. 10, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 have been accepted for presentation, including one selected for oral presentation highlighting the preclinical efficacy of GLIX1 in orthotopic glioblastoma models, at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026), which will be held September 24-27 in

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

Thu, 10 Sep 2026 07:00:00 -0400

Form 6-K BioLineRx Ltd. For: Sep 10

Thu, 10 Sep 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260910/27044950.html

Form 6-K BioLineRx Ltd. For: Aug 28

Fri, 28 Aug 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260828/26993257.html

Form 6-K BioLineRx Ltd. For: Aug 28

Fri, 28 Aug 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260828/26993257.html

Form 6-K BioLineRx Ltd. For: Aug 28

Fri, 28 Aug 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260828/26993257.html

BioLineRx plans $3.75M share offering at $2.78 per ADS

Fri, 28 Aug 2026 08:00:21 -0400

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) has entered into a definitive agreement for a registered direct offering of 1,348,921 American Depositary Shares at $2.78 per ADS, with gross proceeds expected to total $3.75 million before placement agent fees and other expenses.

The Tel Aviv-based company has also agreed to issue warrants to purchase up to 2,023,382 ADSs at an exercise price of $2.78 per ADS through a concurrent private placement. The warrants will expire five years from the issuance date. Each ADS represents 600 ordinary shares with a par value of NIS 0.10 per share.

The offering is expected to close on

BioLineRx plans $3.75M share offering at $2.78 per ADS

Fri, 28 Aug 2026 08:00:21 -0400

The offering is expected to close on

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

Fri, 28 Aug 2026 08:00:00 -0400

TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) at a purchase price of $2.78 per ADS (or per ADS equivalent) through a registered direct offering. In addition, the Company has agreed to issue accompanying warrants to purchase up to

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

Fri, 28 Aug 2026 08:00:00 -0400

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

Fri, 28 Aug 2026 08:00:00 -0400

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

Fri, 28 Aug 2026 08:00:00 -0400

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

Fri, 28 Aug 2026 08:00:00 -0400

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

Fri, 28 Aug 2026 08:00:00 -0400

BioLineRx to Report Second Quarter 2026 Results on August 31, 2026